Molecular and Materials Engineering for Delivery of Peptide Drugs to Treat Type 2 Diabetes
出版年份 2019 全文链接
标题
Molecular and Materials Engineering for Delivery of Peptide Drugs to Treat Type 2 Diabetes
作者
关键词
-
出版物
Advanced Healthcare Materials
Volume -, Issue -, Pages 1801509
出版商
Wiley
发表日期
2019-02-14
DOI
10.1002/adhm.201801509
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study
- (2018) Robert R. Henry et al. DIABETES CARE
- A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide
- (2018) Tine A. Bækdal et al. Expert Opinion on Drug Metabolism & Toxicology
- Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action
- (2018) Caslin A. Gilroy et al. JOURNAL OF CONTROLLED RELEASE
- Biomacromolecules as carriers in drug delivery and tissue engineering
- (2018) Yujie Zhang et al. Acta Pharmaceutica Sinica B
- Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
- (2017) Lene Jensen et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Current and Emerging Technology for Continuous Glucose Monitoring
- (2017) Cheng Chen et al. SENSORS
- Glucose Sensing for Diabetes Monitoring: Recent Developments
- (2017) Danielle Bruen et al. SENSORS
- Synthetic “smart gel” provides glucose-responsive insulin delivery in diabetic mice
- (2017) Akira Matsumoto et al. Science Advances
- One-week glucose control via zero-order release kinetics from an injectable depot of glucagon-like peptide-1 fused to a thermosensitive biopolymer
- (2017) Kelli M. Luginbuhl et al. Nature Biomedical Engineering
- Understanding the Physiology of FGF21
- (2016) Ffolliott Martin Fisher et al. Annual Review of Physiology
- A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
- (2016) Saswata Talukdar et al. Cell Metabolism
- Lessons From Peglispro: IMAGINE How to Improve Drug Development and Affordability
- (2016) Matthew C. Riddle DIABETES CARE
- Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and
- (2016) M. A. Boustani et al. DIABETES OBESITY & METABOLISM
- Basal insulin peglispro: Overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action
- (2016) S. J. Jacober et al. DIABETES OBESITY & METABOLISM
- Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities
- (2016) David Rodbard Diabetes Technology & Therapeutics
- Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
- (2016) Johan Jendle et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
- (2016) Peng Zhang et al. JOURNAL OF CONTROLLED RELEASE
- PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs
- (2016) Peter L. Turecek et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus
- (2016) Wing Yan So et al. MEDICINAL RESEARCH REVIEWS
- How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
- (2016) Araceli Muñoz-Garach et al. Diabetes Therapy
- How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
- (2016) Araceli Muñoz-Garach et al. Diabetes Therapy
- A brush-polymer/exendin-4 conjugate reduces blood glucose levels for up to five days and eliminates poly(ethylene glycol) antigenicity
- (2016) Yizhi Qi et al. Nature Biomedical Engineering
- Factors affecting therapeutic compliance: A review from the patient’s perspective
- (2016) Shu-Chuen Li Therapeutics and Clinical Risk Management
- Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
- (2015) William R. Strohl BIODRUGS
- Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
- (2015) Lisbeth V. Jacobsen et al. CLINICAL PHARMACOKINETICS
- The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future
- (2015) CJ Bailey CLINICAL PHARMACOLOGY & THERAPEUTICS
- Protein–polymer conjugation—moving beyond PEGylation
- (2015) Yizhi Qi et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Peptide therapeutics: current status and future directions
- (2015) Keld Fosgerau et al. DRUG DISCOVERY TODAY
- Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2015) Hannah A. Blair et al. DRUGS
- Smart approaches to glucose-responsive drug delivery
- (2015) Matthew J. Webber et al. JOURNAL OF DRUG TARGETING
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Five-Year Efficacy and Safety Data of Exenatide Once Weekly
- (2015) Carol H. Wysham et al. MAYO CLINIC PROCEEDINGS
- Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery
- (2015) Jicheng Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fc fusion as a platform technology: potential for modulating immunogenicity
- (2015) Ditza Levin et al. TRENDS IN BIOTECHNOLOGY
- Degludec: the new ultra-long insulin analogue
- (2015) Marcos Antonio Tambascia et al. Diabetology & Metabolic Syndrome
- Challenges Associated with Insulin Therapy in Type 2 Diabetes Mellitus
- (2014) Steven Edelman et al. AMERICAN JOURNAL OF MEDICINE
- Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes
- (2014) Robert R. Henry et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Therapeutic Protein–Polymer Conjugates: Advancing Beyond PEGylation
- (2014) Emma M. Pelegri-O’Day et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Inventing new medicines: The FGF21 story
- (2014) Alexei Kharitonenkov et al. Molecular Metabolism
- GLP-1 receptor agonists: a review of head-to-head clinical studies
- (2014) Jennifer M. Trujillo et al. Therapeutic Advances in Endocrinology and Metabolism
- Predicting Transition Temperatures of Elastin-Like Polypeptide Fusion Proteins
- (2013) Trine Christensen et al. BIOMACROMOLECULES
- A Unified Model for De Novo Design of Elastin-like Polypeptides with Tunable Inverse Transition Temperatures
- (2013) Jonathan R. McDaniel et al. BIOMACROMOLECULES
- A New-Generation Continuous Glucose Monitoring System: Improved Accuracy and Reliability Compared with a Previous-Generation System
- (2013) Mark Christiansen et al. Diabetes Technology & Therapeutics
- Burden of treatment for chronic illness: a concept analysis and review of the literature
- (2013) Adem Sav et al. HEALTH EXPECTATIONS
- A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection
- (2013) M. Amiram et al. JOURNAL OF CONTROLLED RELEASE
- Sortase-Catalyzed Initiator Attachment Enables High Yield Growth of a Stealth Polymer from the C Terminus of a Protein
- (2013) Yizhi Qi et al. MACROMOLECULAR RAPID COMMUNICATIONS
- Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control
- (2013) M. Amiram et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes
- (2012) R. M. Bergenstal et al. DIABETES CARE
- Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
- (2012) R. E. Ratner et al. DIABETES OBESITY & METABOLISM
- GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence
- (2012) A. R. Meloni et al. DIABETES OBESITY & METABOLISM
- Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes
- (2012) T. Heise et al. DIABETES OBESITY & METABOLISM
- Fc-fusion proteins: new developments and future perspectives
- (2012) Daniel M. Czajkowsky et al. EMBO Molecular Medicine
- Oral delivery of therapeutic protein/peptide for diabetes – Future perspectives
- (2012) M.R. Rekha et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
- (2012) Ib Jonassen et al. PHARMACEUTICAL RESEARCH
- Efficacy and safety of ultra-long-acting insulin degludec
- (2012) Ammar Wakil et al. Therapeutic Advances in Endocrinology and Metabolism
- FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents
- (2011) J. Mu et al. DIABETES
- Glucose and pH dual-responsive concanavalin A based microhydrogels for insulin delivery
- (2011) Ruixue Yin et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
- (2010) Katrin Knop et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Elastin-like polypeptides: Biomedical applications of tunable biopolymers
- (2010) Sarah R. MacEwan et al. BIOPOLYMERS
- A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects
- (2010) A. Khedkar et al. DIABETES OBESITY & METABOLISM
- Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
- (2010) Wolfgang Glaesner et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Liraglutide
- (2010) Daniel J. Drucker et al. NATURE REVIEWS DRUG DISCOVERY
- Chemical generation of bispecific antibodies
- (2010) V. R. Doppalapudi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
- (2009) M. A. Bush et al. DIABETES OBESITY & METABOLISM
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
- (2009) Volker Schellenberger et al. NATURE BIOTECHNOLOGY
- In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics
- (2009) W. Gao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
- (2008) Jessica E. Matthews et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now